Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 31 04:00PM ET
8.59
Dollar change
-0.25
Percentage change
-2.83
%
IndexRUT P/E- EPS (ttm)-5.27 Insider Own9.95% Shs Outstand49.42M Perf Week-10.33%
Market Cap424.54M Forward P/E- EPS next Y-0.79 Insider Trans-2.11% Shs Float44.51M Perf Month-13.41%
Income-241.08M PEG- EPS next Q-1.12 Inst Own89.53% Short Float11.21% Perf Quarter-34.13%
Sales89.04M P/S4.77 EPS this Y24.60% Inst Trans3.45% Short Ratio10.17 Perf Half Y-48.38%
Book/sh7.06 P/B1.22 EPS next Y82.52% ROA-38.52% Short Interest4.99M Perf Year-33.36%
Cash/sh5.87 P/C1.46 EPS next 5Y13.60% ROE-63.94% 52W Range8.81 - 28.80 Perf YTD-52.14%
Dividend Est.- P/FCF- EPS past 5Y- ROI-51.56% 52W High-70.17% Beta1.21
Dividend TTM- Quick Ratio3.53 Sales past 5Y72.63% Gross Margin37.75% 52W Low-2.55% ATR (14)0.58
Dividend Ex-Date- Current Ratio3.53 EPS Y/Y TTM16.62% Oper. Margin-277.01% RSI (14)31.95 Volatility5.47% 5.79%
Employees344 Debt/Eq0.46 Sales Y/Y TTM-8.18% Profit Margin-270.74% Recom1.30 Target Price37.30
Option/ShortYes / Yes LT Debt/Eq0.34 EPS Q/Q36.74% Payout- Rel Volume1.02 Prev Close8.84
Sales Surprise-2.95% EPS Surprise18.70% Sales Q/Q11.60% EarningsNov 06 AMC Avg Volume490.57K Price8.59
SMA20-11.75% SMA50-20.78% SMA200-40.71% Trades Volume501,705 Change-2.83%
Date Action Analyst Rating Change Price Target Change
Oct-10-24Resumed Raymond James Outperform $18
Jun-07-24Initiated Goldman Buy $38
Mar-11-24Initiated H.C. Wainwright Buy $36
Mar-08-24Upgrade RBC Capital Mkts Sector Perform → Outperform $20 → $35
Mar-06-24Upgrade Leerink Partners Market Perform → Outperform $37
Feb-21-24Resumed Raymond James Outperform $45
Nov-01-23Initiated Stifel Buy $35
Jun-02-23Initiated Robert W. Baird Outperform $42
Jun-23-22Initiated Berenberg Buy $61
Dec-15-21Initiated Wedbush Neutral $29
Oct-30-24 07:05AM
Oct-21-24 07:05AM
Oct-18-24 07:05AM
Oct-17-24 03:04PM
Sep-23-24 04:05PM
07:05AM Loading…
Sep-17-24 07:05AM
Sep-04-24 09:15AM
Sep-03-24 01:33PM
08:04AM
Aug-29-24 04:05PM
Aug-27-24 07:05AM
Aug-08-24 07:05AM
06:00AM
Aug-06-24 09:55AM
Aug-01-24 05:45PM
04:46PM Loading…
04:46PM
04:05PM
07:03AM
Jul-30-24 07:01PM
Jul-28-24 09:09AM
Jul-25-24 07:05AM
Jul-12-24 09:59AM
Jun-27-24 10:05AM
Jun-26-24 04:36PM
Jun-25-24 04:32AM
Jun-24-24 12:56PM
07:05AM
Jun-21-24 04:28PM
06:40AM
Jun-18-24 07:05AM
07:02AM Loading…
07:02AM
Jun-12-24 08:00AM
07:05AM
Jun-05-24 07:05AM
May-15-24 11:38AM
May-10-24 02:30PM
07:05AM
May-09-24 03:53PM
11:11AM
07:11AM
03:46AM
May-08-24 09:56PM
05:40PM
04:44PM
04:05PM
May-01-24 07:05AM
Apr-24-24 07:05AM
Mar-28-24 01:09PM
07:05AM
Mar-27-24 04:05PM
Mar-18-24 07:00PM
Mar-13-24 08:00AM
Mar-11-24 07:05AM
Mar-08-24 01:29AM
Mar-06-24 11:20PM
04:10PM
11:33AM
03:01AM
Mar-05-24 07:05AM
Feb-29-24 04:57PM
Feb-28-24 11:05AM
09:36AM
Feb-27-24 05:35PM
04:41PM
04:32PM
04:05PM
Feb-21-24 07:05AM
Feb-17-24 12:07AM
Feb-08-24 09:36AM
04:50AM
Feb-07-24 11:40AM
07:05AM
Jan-31-24 07:05AM
Jan-18-24 09:01PM
Jan-16-24 02:47PM
Jan-10-24 07:05AM
Jan-09-24 06:20PM
Jan-08-24 07:05AM
Dec-22-23 09:01AM
Nov-29-23 07:05AM
Nov-16-23 09:55AM
Nov-09-23 04:46PM
06:37AM
Nov-08-23 04:42PM
04:05PM
Nov-07-23 07:05AM
Nov-03-23 06:53PM
Nov-01-23 07:05AM
Oct-30-23 07:05AM
Oct-05-23 07:05AM
Oct-03-23 04:05PM
Sep-26-23 07:05AM
Sep-05-23 07:05AM
Aug-30-23 07:05AM
Aug-23-23 04:05PM
Aug-02-23 05:55PM
04:41PM
04:05PM
Aug-01-23 04:05PM
Jul-26-23 07:05AM
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KARABELAS ARGERIS NDirectorOct 01 '24Option Exercise3.7610,00037,60021,286Oct 02 04:31 PM
KARABELAS ARGERIS NDirectorOct 01 '24Sale10.1110,000101,05211,286Oct 02 04:31 PM
KARABELAS ARGERIS NDirectorSep 03 '24Option Exercise3.7610,00037,60021,286Sep 04 08:20 PM
KARABELAS ARGERIS NDirectorSep 03 '24Sale11.5610,000115,58811,286Sep 04 08:20 PM
Mills Kenneth T.DirectorAug 08 '24Option Exercise0.8536,31630,869444,351Aug 12 04:58 PM
KARABELAS ARGERIS NDirectorAug 01 '24Option Exercise3.8510,10038,87421,386Aug 05 06:39 PM
KARABELAS ARGERIS NDirectorAug 01 '24Sale13.5110,100136,45411,286Aug 05 06:39 PM
Simpson CurranChief Executive OfficerAug 01 '24Sale15.001001,500170,037Aug 05 06:39 PM
ARGERIS N KARABELASDirectorAug 01 '24Proposed Sale14.2531,000441,750Aug 01 04:34 PM
KARABELAS ARGERIS NDirectorJul 29 '24Option Exercise12.7411,000140,14022,286Jul 30 05:01 PM
KARABELAS ARGERIS NDirectorJul 29 '24Sale15.0411,000165,49511,286Jul 30 05:01 PM
Simpson CurranChief Executive OfficerJul 29 '24Sale15.049,648145,106170,137Jul 30 05:01 PM
CURRAN M SIMPSONDirectorJul 29 '24Proposed Sale14.3325,106359,769Jul 29 04:13 PM
Mills Kenneth T.DirectorJul 25 '24Option Exercise3.7615,36957,787423,404Jul 26 05:00 PM
Mills Kenneth T.DirectorJul 24 '24Option Exercise3.7612,22145,951420,256Jul 26 05:00 PM
Mills Kenneth T.DirectorJul 25 '24Sale13.9615,369214,501408,035Jul 26 05:00 PM
Mills Kenneth T.DirectorJul 24 '24Sale13.7812,221168,433408,035Jul 26 05:00 PM
Mills Kenneth T.DirectorJul 17 '24Option Exercise3.762,2108,310410,245Jul 18 05:05 PM
Mills Kenneth T.DirectorJul 16 '24Option Exercise3.76200752408,235Jul 18 05:05 PM
Mills Kenneth T.DirectorJul 17 '24Sale13.772,21030,440408,035Jul 18 05:05 PM
Mills Kenneth T.DirectorJul 16 '24Sale13.762002,752408,035Jul 18 05:05 PM
KARABELAS ARGERIS NDirectorJul 01 '24Option Exercise3.7610,00037,60021,286Jul 03 07:55 AM
KARABELAS ARGERIS NDirectorJul 01 '24Sale11.2710,000112,69111,286Jul 03 07:55 AM
Mills Kenneth T.President and CEOMay 14 '24Option Exercise3.7615,00056,400423,035May 16 05:06 PM
Mills Kenneth T.President and CEOMay 14 '24Sale15.8115,000237,222408,035May 16 05:06 PM
Mills Kenneth T.President and CEOApr 15 '24Option Exercise3.7615,00056,400423,035Apr 17 05:05 PM
Mills Kenneth T.President and CEOApr 15 '24Sale18.1915,000272,871408,035Apr 17 05:05 PM
Vasista VittalChief Financial OfficerMar 19 '24Option Exercise3.7620,04175,354246,534Mar 21 05:20 PM
Mills Kenneth T.President and CEOMar 14 '24Option Exercise3.7615,00056,400423,035Mar 18 05:03 PM
Mills Kenneth T.President and CEOMar 14 '24Sale21.8615,000327,942408,035Mar 18 05:03 PM
PAKOLA STEVEChief Medical OfficerMar 05 '24Option Exercise22.2512,878286,536120,070Mar 07 06:05 PM
PAKOLA STEVEChief Medical OfficerMar 05 '24Sale28.3612,878365,220107,192Mar 07 06:05 PM
Mills Kenneth T.President and CEOFeb 14 '24Option Exercise3.7615,00056,400423,035Feb 16 06:28 PM
Mills Kenneth T.President and CEOFeb 14 '24Sale16.7615,000251,349408,035Feb 16 06:28 PM
Mills Kenneth T.President and CEOJan 16 '24Option Exercise3.7645,000169,200453,035Jan 18 06:39 PM
Mills Kenneth T.President and CEOJan 16 '24Sale15.1845,000682,992408,035Jan 18 06:39 PM
PAKOLA STEVEChief Medical OfficerJan 03 '24Sale17.3917,237299,789107,192Jan 04 04:23 PM
Mills Kenneth T.President and CEODec 19 '23Option Exercise3.6645,000164,835400,289Dec 21 01:38 PM
Mills Kenneth T.President and CEODec 19 '23Sale19.6845,000885,825355,289Dec 21 01:38 PM